Premium
Genetic advances uncover mechanisms of chemotherapy‐induced peripheral neuropathy
Author(s) -
Chua KC,
Kroetz DL
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.590
Subject(s) - chemotherapy induced peripheral neuropathy , medicine , vinca , peripheral neuropathy , toxicity , chemotherapy , thalidomide , pharmacology , bioinformatics , oncology , biology , multiple myeloma , endocrinology , diabetes mellitus
Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting toxicity experienced in 30–40% of patients undergoing treatment with various chemotherapeutics, including taxanes, vinca alkaloids, epothilones, proteasome inhibitors, and thalidomide. Importantly, CIPN significantly affects a patient's quality of life. Recent genetic association studies are enhancing our understanding of CIPN pathophysiology and serve as a foundation for identification of genetic biomarkers to predict toxicity risk and for the development of novel strategies for prevention and treatment.